Singapore, Oct. 30 -- South Korea-based SK pharmteco and LOTTE BIOLOGICS have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the global antibody-drug conjugate (ADC) market.

Through this collaboration, the two companies will jointly investigate providing integrated, one-stop contract development and manufacturing organisation (CDMO) services to global clients, offering differentiated ADC solutions that span from development to commercial manufacturing.

LOTTE BIOLOGICS will utilize its cGMP manufacturing capabilities and global quality competitiveness at its Syracuse Bio Campus in the US to deliver high-quality bioconjugation and drug substance manufacturing services.

Meanwhile, SK p...